Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 87

1.

Input of recombinant phenotyping for the characterization of a novel acyclovir-resistance mutation identified in a patient with recurrent herpetic keratitis.

Robinet-Perrin A, Tumiotto C, Cornut T, Santoni A, Touboul D, Goupil-Gouyette T, Garrigue I, Boutolleau D, Burrel S.

Antiviral Res. 2019 Aug;168:183-186. doi: 10.1016/j.antiviral.2019.06.007. Epub 2019 Jun 11.

PMID:
31199933
2.

Added value of ultra-deep sequencing (UDS) approach for detection of genotypic antiviral resistance of herpes simplex virus (HSV).

Mercier-Darty M, Boutolleau D, Rodriguez C, Burrel S.

Antiviral Res. 2019 Aug;168:128-133. doi: 10.1016/j.antiviral.2019.05.017. Epub 2019 May 31.

PMID:
31158412
3.

Multirecombinant Enterovirus A71 Subgenogroup C1 Isolates Associated with Neurologic Disease, France, 2016-2017.

Ngangas ST, Lukashev A, Jugie G, Ivanova O, Mansuy JM, Mengelle C, Izopet J, L'honneur AS, Rozenberg F, Leyssene D, Hecquet D, Marque-Juillet S, Boutolleau D, Burrel S, Peigue-Lafeuille H, Archimbaud C, Benschop K, Henquell C, Mirand A, Bailly JL.

Emerg Infect Dis. 2019 Jun;25(6):1204-1208. doi: 10.3201/eid2506.181460.

4.

Comparison of Anti-Viral Activity of Frog Skin Anti-Microbial Peptides Temporin-Sha and [K³]SHa to LL-37 and Temporin-Tb against Herpes Simplex Virus Type 1.

Roy M, Lebeau L, Chessa C, Damour A, Ladram A, Oury B, Boutolleau D, Bodet C, Lévêque N.

Viruses. 2019 Jan 18;11(1). pii: E77. doi: 10.3390/v11010077.

5.

Antiviral effects of Cacicol®, a heparan sulfate biomimetic for corneal regeneration therapy, for herpes simplex virus type-1 and varicella zoster virus infection.

Deback C, Rousseau A, Breckler M, Molet L, Boutolleau D, Burrel S, Roque-Afonso AM, Labetoulle M.

Antivir Ther. 2018;23(8):665-675. doi: 10.3851/IMP3254.

PMID:
30028308
6.

Clinical management of respiratory syndrome in patients hospitalized for suspected Middle East respiratory syndrome coronavirus infection in the Paris area from 2013 to 2016.

Bleibtreu A, Jaureguiberry S, Houhou N, Boutolleau D, Guillot H, Vallois D, Lucet JC, Robert J, Mourvillier B, Delemazure J, Jaspard M, Lescure FX, Rioux C, Caumes E, Yazdanapanah Y.

BMC Infect Dis. 2018 Jul 16;18(1):331. doi: 10.1186/s12879-018-3223-5.

7.

Utility of ultra-deep sequencing for detection of varicella-zoster virus antiviral resistance mutations.

Mercier-Darty M, Boutolleau D, Lepeule R, Rodriguez C, Burrel S.

Antiviral Res. 2018 Mar;151:20-23. doi: 10.1016/j.antiviral.2018.01.008. Epub 2018 Jan 12.

PMID:
29337163
8.

A European multi-centre External Quality Assessment (EQA) study on phenotypic and genotypic methods used for Herpes Simplex Virus (HSV) drug resistance testing.

Afshar B, Bibby DF, Piorkowska R, Ohemeng-Kumi N, Snoeck R, Andrei G, Gillemot S, Morfin F, Frobert E, Burrel S, Boutolleau D, Crowley B, Mbisa JL.

J Clin Virol. 2017 Nov;96:89-93. doi: 10.1016/j.jcv.2017.10.002. Epub 2017 Oct 6.

PMID:
29031157
9.

Recurrent herpetic keratitis despite antiviral prophylaxis: A virological and pharmacological study.

Rousseau A, Boutolleau D, Titier K, Bourcier T, Chiquet C, Weber M, Colin J, Gueudry J, M'Garrech M, Bodaghi B, Burrel S, Agut H, Deback C; HEDGOF (Herpes Eye Disease Group of France), Labetoulle M.

Antiviral Res. 2017 Oct;146:205-212. doi: 10.1016/j.antiviral.2017.09.013. Epub 2017 Sep 20.

PMID:
28939476
10.

Ancient Recombination Events between Human Herpes Simplex Viruses.

Burrel S, Boutolleau D, Ryu D, Agut H, Merkel K, Leendertz FH, Calvignac-Spencer S.

Mol Biol Evol. 2017 Jul 1;34(7):1713-1721. doi: 10.1093/molbev/msx113.

11.

Procalcitonin for clinical decisions on influenza-like illness in emergency department during influenza a(H1N1)2009 pandemic.

Canavaggio P, Boutolleau D, Goulet H, Riou B, Hausfater P.

Biomarkers. 2018 Feb;23(1):10-13. doi: 10.1080/1354750X.2016.1276626. Epub 2017 Jan 12.

PMID:
28010128
12.

Genotypic resistance of cytomegalovirus to antivirals in hematopoietic stem cell transplant recipients from Portugal: A retrospective study.

Campos AB, Ribeiro J, Pinho Vaz C, Campilho F, Branca R, Campos A Jr, Baldaque I, Medeiros R, Boutolleau D, Sousa H.

Antiviral Res. 2017 Feb;138:86-92. doi: 10.1016/j.antiviral.2016.10.016. Epub 2016 Nov 22.

PMID:
27887982
13.

Où en est la recherche sur les antiviraux ?

Agut H, Burrel S, Bonnafous P, Boutolleau D.

Rev Prat. 2016 Nov;66(9):1007-1014. French.

PMID:
30512372
14.

Herpes simplex virus type 2: Cluster of unrelated cases in an intensive care unit.

Troché G, Marque Juillet S, Burrel S, Boutolleau D, Bédos JP, Legriel S.

Am J Infect Control. 2016 Oct 1;44(10):1178-1180. doi: 10.1016/j.ajic.2016.03.035. Epub 2016 May 16.

PMID:
27198455
15.

Complementary assays for monitoring susceptibility of varicella-zoster virus resistance to antivirals.

Perrier M, Désiré N, Deback C, Agut H, Boutolleau D, Burrel S.

J Virol Methods. 2016 Jul;233:10-4. doi: 10.1016/j.jviromet.2016.03.006. Epub 2016 Mar 16.

PMID:
26994966
16.

Human cytomegalovirus antiviral drug resistance in hematopoietic stem cell transplantation: current state of the art.

Campos AB, Ribeiro J, Boutolleau D, Sousa H.

Rev Med Virol. 2016 May;26(3):161-82. doi: 10.1002/rmv.1873. Epub 2016 Mar 14. Review.

PMID:
26990717
17.

Adenovirus related lymphohistiocytic hemophagocytosis: Case report and literature review.

Mellon G, Henry B, Aoun O, Boutolleau D, Laparra A, Mayaux J, Sanson M, Caumes E.

J Clin Virol. 2016 May;78:53-6. doi: 10.1016/j.jcv.2016.03.011. Epub 2016 Mar 10. Review.

PMID:
26985594
18.

Determinants of a Low CD4/CD8 Ratio in HIV-1-Infected Individuals Despite Long-term Viral Suppression.

Caby F, Guihot A, Lambert-Niclot S, Guiguet M, Boutolleau D, Agher R, Valantin MA, Tubiana R, Calvez V, Marcelin AG, Carcelain G, Autran B, Costagliola D, Katlama C.

Clin Infect Dis. 2016 May 15;62(10):1297-1303. doi: 10.1093/cid/ciw076. Epub 2016 Feb 14.

PMID:
26908792
19.

High conservation of herpes simplex virus UL5/UL52 helicase-primase complex in the era of new antiviral therapies.

Collot M, Rouard C, Brunet C, Agut H, Boutolleau D, Burrel S.

Antiviral Res. 2016 Apr;128:1-6. doi: 10.1016/j.antiviral.2016.01.015. Epub 2016 Jan 28.

PMID:
26826441
20.

Atypical ocular manifestation of primary varicella zoster virus infection as the first manifestation of AIDS.

Alghamdi A, Palich R, Calin R, Hussenet C, Papo M, Boutolleau D, Mathian A, Galanaud D, Le Hoang P, Caumes E, Katlama C, Bodaghi B, Touitou V, Pourcher-Martinez V.

AIDS. 2016 Feb 20;30(4):674-6. doi: 10.1097/QAD.0000000000000981. No abstract available.

PMID:
26825036
21.

Tenofovir Gel to Prevent HSV-2 Infection.

Agut H, Burrel S, Boutolleau D.

N Engl J Med. 2015 Nov 12;373(20):1980. doi: 10.1056/NEJMc1511338. No abstract available.

PMID:
26559586
22.

Genetic Diversity within Alphaherpesviruses: Characterization of a Novel Variant of Herpes Simplex Virus 2.

Burrel S, Désiré N, Marlet J, Dacheux L, Seang S, Caumes E, Bourhy H, Agut H, Boutolleau D.

J Virol. 2015 Dec;89(24):12273-83. doi: 10.1128/JVI.01959-15. Epub 2015 Sep 23.

23.

Incidence and risk factors for hemorrhagic cystitis in unmanipulated haploidentical transplant recipients.

Ruggeri A, Roth-Guepin G, Battipaglia G, Mamez AC, Malard F, Gomez A, Brissot E, Belhocine R, Vekhoff A, Lapusan S, Isnard F, Legrand O, Gozlan J, Boutolleau D, Ledraa T, Labopin M, Rubio MT, Mohty M.

Transpl Infect Dis. 2015 Dec;17(6):822-30. doi: 10.1111/tid.12455. Epub 2015 Nov 25.

PMID:
26354178
24.

Management of multidrug-resistant CMV infection in immunocompromised patients: case report of a heart-transplant recipient and review of the literature.

Deback C, Burrel S, Varnous S, Carcelain G, Conan F, Aït-Arkoub Z, Autran B, Gandjbakhch I, Agut H, Boutolleau D.

Antivir Ther. 2015;20(2):249-54. doi: 10.3851/IMP2818. Epub 2014 Jun 25. Review.

PMID:
25219330
25.

Resistance of herpes simplex viruses to acyclovir: an update from a ten-year survey in France.

Frobert E, Burrel S, Ducastelle-Lepretre S, Billaud G, Ader F, Casalegno JS, Nave V, Boutolleau D, Michallet M, Lina B, Morfin F.

Antiviral Res. 2014 Nov;111:36-41. doi: 10.1016/j.antiviral.2014.08.013. Epub 2014 Sep 8.

PMID:
25218782
26.

Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism.

Pilorgé L, Burrel S, Aït-Arkoub Z, Agut H, Boutolleau D.

Antiviral Res. 2014 Nov;111:8-12. doi: 10.1016/j.antiviral.2014.08.014. Epub 2014 Sep 4.

PMID:
25194992
27.

Impact of HIV-1 infection on herpes simplex virus type 2 genetic variability among co-infected individuals.

Abrão EP, Burrel S, Désiré N, Bonnafous P, Godet A, Caumes E, Agut H, Boutolleau D.

J Med Virol. 2015 Mar;87(3):357-65. doi: 10.1002/jmv.24061. Epub 2014 Sep 1.

PMID:
25174847
28.

Cytomegalovirus infection in patients who underwent allogeneic hematopoietic stem cell transplantation in Portugal: a five-year retrospective review.

Sousa H, Boutolleau D, Ribeiro J, Teixeira AL, Pinho Vaz C, Campilho F, Branca R, Campos A Jr, Baldaque I, Medeiros R.

Biol Blood Marrow Transplant. 2014 Dec;20(12):1958-67. doi: 10.1016/j.bbmt.2014.08.010. Epub 2014 Aug 17.

29.

Efficacy and safety of aciclovir mucoadhesive buccal tablet in immunocompetent patients with labial herpes (LIP Trial): a double-blind, placebo-controlled, self-initiated trial.

Bieber T, Chosidow O, Bodsworth N, Tyring S, Hercogova J, Bloch M, Davis M, Lewis M, Boutolleau D, Attali P; LIP Study Group.

J Drugs Dermatol. 2014 Jul;13(7):791-8.

PMID:
25007361
30.

Helicase-primase inhibitor pritelivir for HSV-2 infection.

Burrel S, Rouard C, Boutolleau D.

N Engl J Med. 2014 Apr 24;370(17):1663-4. doi: 10.1056/NEJMc1402071. No abstract available.

PMID:
24758629
31.

Low titers of serum antibodies inhibiting hemagglutination predict fatal fulminant influenza A(H1N1) 2009 infection.

Guihot A, Luyt CE, Parrot A, Rousset D, Cavaillon JM, Boutolleau D, Fitting C, Pajanirassa P, Mallet A, Fartoukh M, Agut H, Musset L, Zoorob R, Kirilovksy A, Combadière B, van der Werf S, Autran B, Carcelain G; FluBAL Study Group.

Am J Respir Crit Care Med. 2014 May 15;189(10):1240-9. doi: 10.1164/rccm.201311-2071OC.

PMID:
24646009
32.

Long-term follow-up of HIV-infected patients once diagnosed with acyclovir-resistant herpes simplex virus infection.

Seang S, Boutolleau D, Burrel S, Regnier S, Epelboin L, Voujon D, Valantin MA, Katlama C, Agut H, Caumes E.

Int J STD AIDS. 2014 Aug;25(9):676-82. doi: 10.1177/0956462413518034. Epub 2014 Feb 17.

PMID:
24535691
33.

Validation of the QIAsymphony RGQ system for DNA quantitation of different BK virus genotypes in whole blood samples.

Burrel S, Brunet C, Hamm N, Gits-Muselli M, Hermet L, Aimé C, Agut H, Boutolleau D.

J Virol Methods. 2014 Feb;196:32-5. doi: 10.1016/j.jviromet.2013.10.030. Epub 2013 Oct 30.

PMID:
24184087
34.

Temporal and spatial compartmentalization of drug-resistant cytomegalovirus (CMV) in a child with CMV meningoencephalitis: implications for sampling in molecular diagnosis.

Frange P, Boutolleau D, Leruez-Ville M, Touzot F, Cros G, Heritier S, Moshous D, Neven B, Fischer A, Blanche S.

J Clin Microbiol. 2013 Dec;51(12):4266-9. doi: 10.1128/JCM.02411-13. Epub 2013 Oct 9.

35.

Surveillance of herpes simplex virus resistance to antivirals: a 4-year survey.

Burrel S, Aime C, Hermet L, Ait-Arkoub Z, Agut H, Boutolleau D.

Antiviral Res. 2013 Nov;100(2):365-72. doi: 10.1016/j.antiviral.2013.09.012. Epub 2013 Sep 25.

PMID:
24075863
36.

Molecular characterization of herpes simplex virus 2 strains by analysis of microsatellite polymorphism.

Burrel S, Ait-Arkoub Z, Voujon D, Deback C, Abrao EP, Agut H, Boutolleau D.

J Clin Microbiol. 2013 Nov;51(11):3616-23. doi: 10.1128/JCM.01714-13. Epub 2013 Aug 21.

37.

Acyclovir-resistant varicella-zoster virus keratitis in an immunocompetent patient.

Gueudry J, Boutolleau D, Gueudin M, Burrel S, Miri A, Bodaghi B, Muraine M.

J Clin Virol. 2013 Sep;58(1):318-20. doi: 10.1016/j.jcv.2013.04.024. Epub 2013 Jun 4.

PMID:
23756055
38.

Phenotypic and genotypic characterization of acyclovir-resistant corneal HSV-1 isolates from immunocompetent patients with recurrent herpetic keratitis.

Burrel S, Boutolleau D, Azar G, Doan S, Deback C, Cochereau I, Agut H, Gabison EE.

J Clin Virol. 2013 Sep;58(1):321-4. doi: 10.1016/j.jcv.2013.05.001. Epub 2013 May 31.

PMID:
23731845
39.

Detection of a new variant of herpes simplex virus type 2 among HIV-1-infected individuals.

Burrel S, Abrao EP, Désiré N, Seang S, Caumes E, Agut H, Boutolleau D.

J Clin Virol. 2013 Jul;57(3):267-9. doi: 10.1016/j.jcv.2013.03.008. Epub 2013 Apr 5. No abstract available.

PMID:
23567026
40.

Impact of novel mutations of herpes simplex virus 1 and 2 thymidine kinases on acyclovir phosphorylation activity.

Burrel S, Bonnafous P, Hubacek P, Agut H, Boutolleau D.

Antiviral Res. 2012 Dec;96(3):386-90. doi: 10.1016/j.antiviral.2012.09.016. Epub 2012 Oct 3.

PMID:
23041200
41.

Routine use of duplex real-time PCR assays including a commercial internal control for molecular diagnosis of opportunistic DNA virus infections.

Burrel S, Fovet C, Brunet C, Ovaguimian L, Hamm N, Conan F, Kalkias L, Agut H, Boutolleau D.

J Virol Methods. 2012 Oct;185(1):136-41. doi: 10.1016/j.jviromet.2012.05.031. Epub 2012 Jul 2.

PMID:
22766177
42.

Emergence of cytomegalovirus resistance to foscarnet in a patient receiving foscarnet salvage therapy for multidrug-resistant HIV infection.

Boutolleau D, Canestri A, Burrel S, Wirden M, Seang S, Clavel-Osorio C, Marcelin AG, Katlama C, Agut H.

J Clin Virol. 2012 Jun;54(2):194-6. doi: 10.1016/j.jcv.2012.02.008. Epub 2012 Mar 6.

PMID:
22398036
43.

Confirmation of the low clinical effect of human herpesvirus-6 and -7 infections after renal transplantation.

Caïola D, Karras A, Flandre P, Boutolleau D, Scieux C, Agut H, Legendre C, Gautheret-Dejean A.

J Med Virol. 2012 Mar;84(3):450-6. doi: 10.1002/jmv.23206.

PMID:
22246831
44.

Clinical and microbiological evaluation of travel-associated respiratory tract infections in travelers returning from countries affected by pandemic A(H1N1) 2009 influenza.

Jauréguiberry S, Boutolleau D, Grandsire E, Kofman T, Deback C, Aït-Arkoub Z, Bricaire F, Agut H, Caumes E.

J Travel Med. 2012 Jan-Feb;19(1):22-7. doi: 10.1111/j.1708-8305.2011.00570.x. Epub 2011 Dec 8.

45.

Genotypic characterization of herpes simplex virus DNA polymerase UL42 processivity factor.

Burrel S, Aït-Arkoub Z, Agut H, Boutolleau D.

Antiviral Res. 2012 Jan;93(1):199-203. doi: 10.1016/j.antiviral.2011.10.016. Epub 2011 Oct 28.

PMID:
22061617
46.

Exhausted cytotoxic control of Epstein-Barr virus in human lupus.

Larsen M, Sauce D, Deback C, Arnaud L, Mathian A, Miyara M, Boutolleau D, Parizot C, Dorgham K, Papagno L, Appay V, Amoura Z, Gorochov G.

PLoS Pathog. 2011 Oct;7(10):e1002328. doi: 10.1371/journal.ppat.1002328. Epub 2011 Oct 20.

47.

Rapid virological diagnosis of central nervous system infections by use of a multiplex reverse transcription-PCR DNA microarray.

Leveque N, Van Haecke A, Renois F, Boutolleau D, Talmud D, Andreoletti L.

J Clin Microbiol. 2011 Nov;49(11):3874-9. doi: 10.1128/JCM.01214-11. Epub 2011 Sep 14.

48.

A fatal case of Human Herpesvirus 6 chronic myocarditis in an immunocompetent adult.

Leveque N, Boulagnon C, Brasselet C, Lesaffre F, Boutolleau D, Metz D, Fornes P, Andreoletti L.

J Clin Virol. 2011 Oct;52(2):142-5. doi: 10.1016/j.jcv.2011.06.017. Epub 2011 Jul 28.

PMID:
21802354
49.

Genotypic characterization of human cytomegalovirus UL97 phosphotransferase natural polymorphism in the era of ganciclovir and maribavir.

Boutolleau D, Burrel S, Agut H.

Antiviral Res. 2011 Jul;91(1):32-5. doi: 10.1016/j.antiviral.2011.04.015. Epub 2011 May 4.

PMID:
21570426
50.

Human NKG2A overrides NKG2C effector functions to prevent autoreactivity of NK cells.

Béziat V, Hervier B, Achour A, Boutolleau D, Marfain-Koka A, Vieillard V.

Blood. 2011 Apr 21;117(16):4394-6. doi: 10.1182/blood-2010-11-319194. No abstract available.

Supplemental Content

Loading ...
Support Center